MBX Biosciences' Phase 3 hypoparathyroidism trial enrolls, obesity pipeline advances
MBX said its pivotal canvuparatide trial is dosing patients, MBX 4291 data remain on track for Q4 2026, and cash on hand extends into 2029.
SEC filing, FDA (9)
2 stories
MBX said its pivotal canvuparatide trial is dosing patients, MBX 4291 data remain on track for Q4 2026, and cash on hand extends into 2029.
SEC filing, FDA (9)
The Carmel, Indiana-based company set board size at eight following the appointment, effective October 20, 2026.
SEC filing